EdgeRock Capital LLC Invests $45,000 in Zoetis Inc. (NYSE:ZTS)

EdgeRock Capital LLC bought a new stake in shares of Zoetis Inc. (NYSE:ZTS) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 239 shares of the company’s stock, valued at approximately $45,000.

Several other large investors have also added to or reduced their stakes in the business. Everpar Advisors LLC acquired a new position in shares of Zoetis during the fourth quarter valued at about $296,000. Gryphon Financial Partners LLC increased its position in Zoetis by 11.8% in the 4th quarter. Gryphon Financial Partners LLC now owns 3,056 shares of the company’s stock valued at $601,000 after buying an additional 322 shares in the last quarter. Sawgrass Asset Management LLC raised its stake in Zoetis by 28.1% during the 4th quarter. Sawgrass Asset Management LLC now owns 55,827 shares of the company’s stock worth $11,019,000 after buying an additional 12,242 shares during the period. Peddock Capital Advisors LLC grew its stake in Zoetis by 10.0% in the fourth quarter. Peddock Capital Advisors LLC now owns 5,938 shares of the company’s stock valued at $1,172,000 after acquiring an additional 540 shares during the period. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its holdings in shares of Zoetis by 16.8% during the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 1,855 shares of the company’s stock valued at $366,000 after acquiring an additional 267 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Buying and Selling at Zoetis

In related news, EVP Roxanne Lagano sold 363 shares of Zoetis stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $197.74, for a total value of $71,779.62. Following the sale, the executive vice president now owns 20,417 shares of the company’s stock, valued at approximately $4,037,257.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 2,209 shares of company stock worth $371,293 over the last three months. 0.16% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages recently issued reports on ZTS. The Goldman Sachs Group cut their target price on Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a report on Monday. HSBC reduced their price objective on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a report on Wednesday. Barclays lowered their target price on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a report on Tuesday, April 23rd. Piper Sandler reissued an “overweight” rating and set a $195.00 price objective (down from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. Finally, StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $211.75.

Zoetis Stock Performance

Shares of ZTS stock traded down $3.53 during trading on Wednesday, hitting $164.92. The company’s stock had a trading volume of 4,669,191 shares, compared to its average volume of 3,195,939. The company has a current ratio of 3.33, a quick ratio of 1.94 and a debt-to-equity ratio of 1.30. The company has a market cap of $75.25 billion, a PE ratio of 31.78, a P/E/G ratio of 2.57 and a beta of 0.86. The business has a fifty day moving average of $167.64 and a 200-day moving average of $178.93. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, May 2nd. The company reported $1.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.04. The firm had revenue of $2.19 billion during the quarter, compared to the consensus estimate of $2.14 billion. Zoetis had a return on equity of 50.34% and a net margin of 27.38%. The business’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.31 EPS. As a group, research analysts anticipate that Zoetis Inc. will post 5.77 earnings per share for the current year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.